FDA Approves ATOVAQUONE AND PROGUANIL HYDROCHLORIDE PEDIATRIC — Glenmark Pharmaceuticals Inc.,USA

January 12 – Glenmark Pharmaceuticals Inc. announced the approval of its generic Atovaquone and Proguanil Hydrochloride for pediatric use, defending its market position against Voltaren Diflunisal previously held by the brand. This clearance expands the company's generic portfolio within the antimalarial sector, potentially capturing a significant revenue share in a niche but essential therapeutic area.